Creatine, guanidinoacetate and homoarginine in statin-induced myopathy.
Amidinotransferases
/ deficiency
Amino Acid Metabolism, Inborn Errors
Animals
Creatine
/ metabolism
Developmental Disabilities
Glycine
/ analogs & derivatives
Guanidinoacetate N-Methyltransferase
/ deficiency
Homoarginine
/ metabolism
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Intellectual Disability
Mice
Muscular Diseases
/ chemically induced
Phosphocreatine
/ metabolism
Speech Disorders
Journal
Amino acids
ISSN: 1438-2199
Titre abrégé: Amino Acids
Pays: Austria
ID NLM: 9200312
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
25
03
2020
accepted:
20
06
2020
pubmed:
1
7
2020
medline:
28
5
2021
entrez:
29
6
2020
Statut:
ppublish
Résumé
Our study evaluated the effect of creatine and homoarginine in AGAT- and GAMT-deficient mice after simvastatin exposure. Balestrino and Adriano suggest that guanidinoacetate might explain the difference between AGAT- and GAMT-deficient mice in simvastatin-induced myopathy. We agree with Balestrino and Adriano that our data shows that (1) creatine possesses a protective potential to ameliorate statin-induced myopathy in humans and mice and (2) homoarginine did not reveal a beneficial effect in statin-induced myopathy. Third, we agree that guanidinoacetate can be phosphorylated and partially compensate for phosphocreatine. In our study, simvastatin-induced damage showed a trend to be less pronounced in GAMT-deficient mice compared with wildtype mice. Therefore, (phospo) guanidinoacetate cannot completely explain the milder phenotype of GAMT-deficient mice, but we agree that it might contribute to ameliorate statin-induced myopathy in GAMT-deficient mice compared with AGAT-deficient mice. Finally, we agree with Balestino and Adriano that AGAT metabolites should further be evaluated as potential treatments in statin-induced myopathy.
Identifiants
pubmed: 32594255
doi: 10.1007/s00726-020-02865-w
pii: 10.1007/s00726-020-02865-w
pmc: PMC7406479
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Phosphocreatine
020IUV4N33
Homoarginine
156-86-5
Guanidinoacetate N-Methyltransferase
EC 2.1.1.2
Amidinotransferases
EC 2.1.4.-
glycocyamine
GO52O1A04E
Creatine
MU72812GK0
Glycine
TE7660XO1C
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
1067-1069Subventions
Organisme : Else Kröner-Fresenius-Stiftung (DE)
ID : 2018_EKES.04
Organisme : Werner-Otto-Stiftung
ID : 5/86
Références
BMJ Case Rep. 2018 Aug 27;2018:
pubmed: 30150340
J Pediatr. 1997 Oct;131(4):626-31
pubmed: 9386672
J Physiol. 2006 Oct 15;576(Pt 2):391-401
pubmed: 16873409
Circulation. 2013 Sep 24;128(13):1451-61
pubmed: 24004504
Hum Mol Genet. 2004 May 1;13(9):905-21
pubmed: 15028668
J Physiol. 2013 Jan 15;591(2):571-92
pubmed: 23129796
Ann Intern Med. 2010 Nov 16;153(10):690-2
pubmed: 21079234
Cardiovasc Res. 2018 Mar 01;114(3):417-430
pubmed: 29236952
Amino Acids. 2020 Apr;52(4):667-669
pubmed: 32172372
Amino Acids. 2011 May;40(5):1271-96
pubmed: 21448658
Amino Acids. 2020 Jan;52(1):73-85
pubmed: 31853708
J Physiol. 2004 Oct 1;560(Pt 1):219-29
pubmed: 15284341